AbbVie (ABBV)
AbbVie's shares experienced a decline despite an earnings per share forecast that exceeded analyst estimates. The discussion examines the company's efforts to revitalize its aesthetics business, including Botox and Juvéderm, highlighting mixed performance within this segment.